American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients.

Autor:	Cuker A; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Tseng EK; Division of Hematology/Oncology; St. Michael's Hospital, University of Toronto, Toronto, ON, Canada., Schünemann HJ; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.; Institut für Evidence in Medicine, Medical Center & Faculty of Medicine, University of Freiburg, Freiburg, Germany., Angchaisuksiri P; Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Blair C; Union, NJ., Dane K; Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD., DeSancho MT; Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY., Diuguid D; Division of Hematology, and., Griffin DO; Division of Infectious Diseases, College of Physicians & Surgeons of Columbia University, New York, NY.; Research and Development at United Health Group, Minnetonka, MN.; Prohealth NY, Lake Success, NY., Kahn SR; Department of Medicine, McGill University, Montreal, QC, Canada., Klok FA; Department of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands., Lee AI; Section of Hematology, Yale School of Medicine, New Haven, CT., Neumann I; Escuela de Medicina, Facultad de Medicina y Ciencia, Universidad San Sebastian, Santiago, Chile., Pai A; Division of Hematology & Oncology, Kaiser Permanente, Oakland/Richmond, CA., Righini M; Division of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland., Sanfilippo KM; Washington University School of Medicine St. Louis, St. Louis, MO., Siegal DM; Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada., Skara M; Cottage Grove, MN., Terrell DR; Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK., Touri K; Toronto, ON, Canada., Akl EA; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon., Al Jabiri R; University of Jordan, Amman, Jordan., Al Jabiri Y; Lincoln Medical Center, Bronx, NY., Boulos M; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Brignardello-Petersen R; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Charide R; Clinical Research Institute, American University of Beirut, Beirut, Lebanon., Colunga-Lozano LE; Department of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico., Dearness K; Library Services, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada., Darzi AJ; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Karam SG; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Morgano GP; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Morsi RZ; Department of Neurology, University of Chicago, Chicago, IL; and., Philip BA; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Benitez YR; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Stevens A; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Solo K; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Wiercioch W; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada., Mustafa RA; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.; Department of Internal Medicine, Division of Nephrology, University of Kansas Medical Center, Kansas City, KS., Nieuwlaat R; Department of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2022 Sep 13; Vol. 6 (17), pp. 4975-4982.
DOI:	10.1182/bloodadvances.2022007940
Abstrakt:	Background: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for patients with COVID-19. Methods: ASH formed a multidisciplinary guideline panel, including 3 patient representatives, and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing systematic evidence reviews (up to January 2022). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 and May 2021 as part of the living phase of these guidelines. Results: The panel made 1 additional recommendation: a conditional recommendation for the use of prophylactic-intensity over therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of thrombotic and bleeding risk. Conclusions: This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation for patients with COVID-19-related critical illness. (© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu